Corlanor and Fedratinib Hydrochloride

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivabradine, which is primarily metabolized by the isoenzyme. According to the product labeling, administration of ivabradine with the moderate CYP450 3A4 inhibitor diltiazem (120 mg twice daily) resulted in approximately 3-fold increases in ivabradine peak plasma concentration (Cmax) and systemic exposure (AUC) compared to administration of ivabradine alone. Likewise, administration with verapamil (120 mg twice daily) increased the Cmax and AUC of ivabradine by approximately 2-fold. Grapefruit juice, another moderate CYP450 3A4 inhibitor, increased ivabradine AUC by a little over 2-fold. Elevated plasma levels of ivabradine may increase the risk of excessive bradycardia and conduction disturbances. MANAGEMENT: Concomitant use of ivabradine with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, some authorities recommend initiating ivabradine at a dosage of 2.5 mg twice daily, provided the resting heart rate is at or above 70 beats per minute and heart rate is closely monitored. References EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports. Available from: URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/medicines/medicines_landingpage.jsp&mid." "Product Information. Corlanor (ivabradine)." Amgen USA, Thousand Oaks, CA. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

GENERALLY AVOID: Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of ivabradine, which is primarily metabolized by the isoenzyme. According to the product labeling, administration of ivabradine with the moderate CYP450 3A4 inhibitor diltiazem (120 mg twice daily) resulted in approximately 3-fold increases in ivabradine peak plasma concentration (Cmax) and systemic exposure (AUC) compared to administration of ivabradine alone. Likewise, administration with verapamil (120 mg twice daily) increased the Cmax and AUC of ivabradine by approximately 2-fold. Grapefruit juice, another moderate CYP450 3A4 inhibitor, increased ivabradine AUC by a little over 2-fold. Elevated plasma levels of ivabradine may increase the risk of excessive bradycardia and conduction disturbances.

MANAGEMENT: Concomitant use of ivabradine with moderate CYP450 3A4 inhibitors should generally be avoided. If coadministration is required, some authorities recommend initiating ivabradine at a dosage of 2.5 mg twice daily, provided the resting heart rate is at or above 70 beats per minute and heart rate is closely monitored.

Corlanor

Generic Name: ivabradine

Brand name: Corlanor

Synonyms: n.a.

What is Corlanor?

Fedratinib Hydrochloride

Generic Name: fedratinib

Brand name: Inrebic

Synonyms: Fedratinib

What is Fedratinib Hydrochloride?